T cells are crucial for immune functions to maintain health and prevent disease. T cell
development occurs in a stepwise process in the thymus and mainly generates CD4+ and …

CD8+ T cells are end effectors of cancer immunity. Most forms of effective cancer
immunotherapy involve CD8+ T cell effector function. Here, we review the current …

Vα24-invariant natural killer T cells (NKTs) have anti-tumor properties that can be enhanced
by chimeric antigen receptors (CARs). Here we report updated interim results from the first-in …

T cells can acquire a broad spectrum of differentiation states following activation. At the
extreme ends of this continuum are short-lived cells equipped with effector machinery and …

Overcoming immune-mediated resistance to PD-1 blockade remains a major clinical
challenge. Enhanced efficacy has been demonstrated in melanoma patients with combined …

Persistent inflammation driven by cytokines such as type-one interferon (IFN-I) can cause
immunosuppression. We show that administration of the Janus kinase 1 (JAK1) inhibitor …

Tissue localization is a critical determinant of T cell immunity. CD8+ T cells are contact-
dependent killers, which requires them to physically be within the tissue of interest to kill …

Identification of mechanisms that program early effector T cells to either terminal effector T
(Teff) or memory T (Tm) cells has important implications for protective immunity against …

Summary Rewiring exhausted CD8+ T (Tex) cells toward functional states remains a
therapeutic challenge. Tex cells are epigenetically programmed by the transcription factor …

Acute myeloid leukemia (AML) is a rapidly progressive malignancy without effective
therapies for refractory disease. So far, chimeric antigen receptor (CAR) T cell therapy in …